Study of Metabolic Syndrome Use Omega-3 Fatty Acids and Low Fat Meal

Metabolic Syndrome Clinical Trial

Official title:

Phase 2 Study of Metabolic Syndrome Use Omega-3 Fatty Acids and Low Fat Meal Replacements

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01768169
• Other study ID #: omega-3 fatty acids
• Status: Recruiting
• Phase: N/A
• First received: December 23, 2012
• Last updated: January 11, 2013
• Start date: April 2012
• Est. completion date: July 2013

Study information

• Verified date: December 2012
• Source: Taipei Medical University Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Taiwan: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Increased understanding of the impact of long chain omega-3 PUFAs in combination with a low fat plant-based diet will contribute to decelerating further escalation of the "epidemics" of obesity, the (pre)metabolic syndrome, and T2DM in Taiwan.

Description:

The metabolic syndrome is a common condition in which different degrees of hypertension, impaired glucose tolerance, atherogenic dyslipidemia, and central fat accumulation, as well as prothrombotic and proinflammatory states cluster together in the same individual. The modified National Cholesterol Education Program, Adult Treatment Panel III guidelines defined the metabolic syndrome subjects as individuals with 3 or more following criterion:

1. Waist circumference: in male ≥90 cm and female ≥80 cm

2. Raised triglycerides: > 150 mg/dL

3. Reduced HDL cholesterol: <40 mg/dL in males, <50 mg/dL in females

4. Raised blood pressure: systolic blood pressure >130 or diastolic blood pressure >85 mmHg

5. Raised fasting plasma glucose: (FPG)>100 mg/dL

Changes in macronutrient composition have been used to promote weight loss and enhance insulin sensitivity, independent of an emphasis on overall calorie ingestion. Protective effects of fish intake on the development of insulin resistance has been reported in prospective epidemiological studies. Further, long chain omega-3 PUFAs supplementation may improve insulin sensitivity in patients with impaired glucose tolerance and in patients with T2DM.

However, this has not been clearly demonstrated in an intervention trial in Taiwan. Furthermore, the effect of supplementation of long chain omega-3 PUFAs on metabolic risk factors and insulin resistance, except for demonstrated benefit in terms of decreased triglycerides, needs further investigation among Asians.

This 13-week, randomized controlled study will assign approximately 200 subjects meeting criteria for the Metabolic Syndrome (50 each) to the following four arms 1) Standard Taiwan Diet plan; 2) Herbalife meal replacement diet program (Low fat diet); 3) Standard Taiwan Diet plan plus healthy oil supplement (Herbalifeline®) and 4) Herbalife meal replacement plan (Low fat diet) plus healthy oil supplement (Herbalifeline®). All participants will meet with a registered dietitian to assist them with their diet efforts.

In this study, we aim to study the effects of low fat diet with reduced omega-6 PUFAs alone and the same low fat diet with omega-3 fatty acids supplementation on cardiometabolic profile and circulating fatty acid profiles in subjects with the metabolic syndrome.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: July 2013
• Est. primary completion date: March 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years to 65 Years

Eligibility

Inclusion Criteria:

• Age 30 to 65 years

• Female subjects must have a negative pregnancy test at screening, must be surgically sterile or at least 6 months postmenopausal or must use a form of birth control measure.

• BMI of 24 to 40 kg/m2 inclusive.

• Subjects must be in good health other than having metabolic syndrome as determined by medical history, physical examination, and screening clinical laboratory including chemistry panel and CBC.

• Must have stable smoking habits (or be now-smokers) for at least 6 months prior to screening and agree not to intend to change such habits during the course of the study.

• Subjects requiring the regular use of any prescription medication may be admitted to the study providing the dose is stable.

• Ethical subjects only will be admitted who are likely to comply with all visits and instructions. This will be determined in the screening phase.

• Body weight must be stable within 2% of change in the last 3 months.

• Subject must sign the Institutional Review Board-approved written informed consent prior to the initiation of any study specific procedures or randomization. A subject will be excluded for any condition that might compromise the ability to give truly informed consent for participation in the study.

Exclusion Criteria:

• Diabetes

• nown or documented coronary heart disease (CHD) (including ECG consistent with prior myocardial infraction), cerebrovascular accident (including transient ischemic attack), peripheral vascular disease (including symptoms of claudication)

• Angina or other chest pain that may indicate CHD

• Clinically significant neoplastic, cardiovascular, hepatic, renal, metabolic, endocrine (untreated or unstable), or psychiatric (untreated or unstable)

• Known abnormal liver function tests greater than 3X upper limit of normal

• Smoker, illicit drug use, or excessive alcohol use

• Medications: Lipid lowering therapy, daily NSAID or greater than 325 mg ASA (PRN use ok), clopidogrel (or equivalent), Coumadin, omega-3 fatty acid supplement, other investigational drugs within 30 days of study entry, high omega-3 fatty acid content in diet within past three months

• Pregnancy or planning pregnancy during the study period

• Sensitivity or allergy to fish

• Subjects who had undergone bypass procedure.

• Any debilitating disease such as tuberculosis, HIV etc.

• Unwillingness to give written informed consent for participation in the study.

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Metabolic Syndrome
• Metabolic Syndrome X
• Syndrome

Intervention

Dietary Supplement:
• fish oil capsule
500 mg of natural fish oil, made up of 30% omega-3 PUFA (EPA:DHA = 3:2)

Locations

Country	Name	City	State
Taiwan	Taipei Mecical University Hospital	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
Taipei Medical University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Metabolic syndrome index	Waist circumference in male =90 cm and female =80 cm; Raised triglycerides: > 150 mg/dL; Reduced HDL cholesterol: <40 mg/dL in males, <50 mg/dL in females; Raised blood pressure: systolic blood pressure >130 or diastolic blood pressure >85 mmHg; Raised fasting plasma glucose: (FPG)>100 mg/dL	Day 1 and up to 12 weeks	Yes